Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 14, 2026
Why Is HeartFlow (HTFL) Stock Up +26.8% Today?

Why Is HeartFlow (HTFL) Stock Up +26.8% Today?

Key Takeaways

  • HeartFlow shares surged approximately 26.8% in early trading Thursday, changing hands around $39.32 versus Wednesday’s close of $31.01.
  • The move was an earnings-driven rally after second-quarter results beat expectations and the company raised its full-year outlook.
  • Plaque Analysis was the standout growth driver, with revenue of $7.8 million coming in about $4 million above internal expectations.
  • Analysts raised price targets following the report, reinforcing bullish sentiment.
  • The stock was trading within roughly 5% of its 52-week high of $41.22.
  • Traders are watching Plaque adoption, second-half execution, and upcoming clinical data readouts.

Opening Summary

HeartFlow, Inc. (HTFL) is a medical technology company that provides AI-powered, non-invasive solutions for diagnosing and managing coronary artery disease. Its shares rallied sharply in early trading Thursday, rising $8.31, or about 26.8%, to $39.32, compared with a prior closing price of $31.01 on Wednesday. The move extended a strong pre-market surge and reflected an enthusiastic market reaction to second-quarter 2026 results released after Wednesday’s close, which beat revenue expectations and included raised full-year guidance.

Q2 Earnings Beat and Raised Full-Year Outlook

HeartFlow (HTFL) reported second-quarter revenue of $64.1 million, up 48% year over year and above the consensus estimate of about $56.6 million. U.S. revenue rose 51% to $59.6 million, while international and other revenue reached $4.5 million. The company’s non-GAAP net loss narrowed to $5.8 million, or $0.07 per share, from $17.6 million, or $2.79 per share, in the same period a year earlier.

Management also raised its full-year 2026 revenue guidance to a range of $246 million to $250 million, implying growth of 40% to 42%, up from a prior outlook of $228 million to $232 million. The company increased its full-year non-GAAP gross margin guidance to approximately 82% and reiterated its target of reaching cash flow profitability by mid-2028.

Plaque Momentum and Margin Expansion

A key driver of the quarter was HeartFlow’s Plaque Analysis business. Plaque revenue of $7.8 million represented about 12% of total revenue and came in roughly $4 million above the company’s expectations. Management said new account activations were ahead of plan and that coverage had reached about 78% of insured lives. The company raised its full-year Plaque revenue outlook to $29 million to $31 million and now expects approximately 1,250 activated Plaque accounts by year-end.

The core FFRCT business also contributed, with U.S. FFRCT revenue growing about 32% during the quarter. Gross margin expanded to 83.3%, up 770 basis points from 75.6% a year earlier, supported by volume leverage, AI-driven efficiencies, and a higher mix of high-margin Plaque revenue.

Analyst Price-Target Increases Reinforce the Move

The earnings-driven stock move was amplified by a wave of analyst activity. Stifel raised its price target on HTFL to $45 from $40 and maintained a Buy rating, citing strength in both the Plaque and FFRCT businesses. J.P. Morgan maintained a Buy rating with a $45 price target, while Wells Fargo maintained a Buy rating with a $39 target. The analyst response reinforced the view that HeartFlow’s accelerating revenue growth and improving margins are gaining credibility on Wall Street.

Market Context and Trading Activity

The rally appeared to be company-specific rather than driven by broad market or sector action. Shares jumped more than 20% in pre-market trading and extended those gains after the opening bell, moving from Wednesday’s close of $31.01 to around $39.32 by mid-morning Thursday. Wednesday’s regular-session volume of roughly 1.07 million shares was more than double the prior nine-session average of about 425,000 shares, indicating elevated investor interest even before the earnings announcement. The stock also traded near the upper end of its 52-week range, approaching its 52-week high of $41.22.

What Comes Next for HTFL

Investors will now focus on whether HTFL can sustain its Plaque adoption momentum and deliver on its raised revenue and margin guidance through the second half of 2026. Key catalysts include continued account activations, reimbursement developments, the DECIDE one-year outcomes expected in the fourth quarter, and broader evidence supporting expansion into the asymptomatic patient market. Risks include an ongoing competitive and regulatory environment, persistent GAAP losses, and a premium valuation that leaves the shares sensitive to any execution shortfall.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing traders to explore automated approaches matched to different market environments. Readers interested in AI-driven market analysis can visit the page to review the latest top-performing strategies.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HTFL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


HTFL in upward trend: price rose above 50-day moving average on August 07, 2026

HTFL moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend. In of 8 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 31, 2026. You may want to consider a long position or call options on HTFL as a result. In of 21 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HTFL just turned positive on July 29, 2026. Looking at past instances where HTFL's MACD turned positive, the stock continued to rise in of 8 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HTFL advanced for three days, in of 69 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTFL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HTFL broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HTFL entered a downward trend on July 31, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.372) is normal, around the industry mean (7.196). HTFL has a moderately low P/E Ratio (0.000) as compared to the industry average of (51.233). HTFL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.661). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (13.966) is also within normal values, averaging (6.772).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HTFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 2.79B. The market cap for tickers in the group ranges from 708 to 41.04B. VEEV holds the highest valuation in this group at 41.04B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was 7%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 29%. CTEV experienced the highest price growth at 57%, while HCAT experienced the biggest fall at -24%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was -56%. For the same stocks of the Industry, the average monthly volume growth was 18% and the average quarterly volume growth was -36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 75
Price Growth Rating: 52
SMR Rating: 87
Profit Risk Rating: 97
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
HTFL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry ServicestotheHealthIndustry

Profile
Details
Interact to see
Advertisement
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Golar LNG (GLNG) has remained resilient in recent trading, hovering near the top of its 52-week range as investor interest in floating LNG infrastructure continues to build. The stock is underpinned by a deep FLNG order backlog, steady production from operating assets, and improving financial flexibility.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.